Photos: 

Some evaluation reports are public and can be downloaded from this website, while others are restricted to MSF users and can only be accessed via Tukul. This limitation is mainly due to the sensitive nature of the operational contexts and the resulting content. However, there are internal discussions about making all evaluation reports publicly searchable. If you are an MSF association member, reports are made available on various associate platforms such as www.insideOCB.com.

This document describes the project Lessons identified at the end of the market entry planning phase for MSF in Finland. It summarises the successes and challenges encountered during the project, lists the learning themes arising from these successes and challenges, and includes a set of lessons derived from an analysis of these learning points. The Annex contains a proposed (brief) framework with criteria and pre-requisites for a successful Market Entry Plan in MSF based on this experience. NOTE: This is not an evaluation and therefore there is no ambition for independent judgement.

This Retrospect was facilitated by the Stockholm Evaluation Unit on behalf of the Project Team. The report has been prepared by Timothy McCann.
30/10/2017

After a very intense and difficult one week response to support the MoH Hospital with specialised burn trauma capacity, the cell and mission brought in Stockholm Evaluation Unit to facilitate an internal Retrospect process to help the team identify key lessons and to bring closure to the project team. Note, the Retrospect does not aim to make independent judgement or analysis, only to facilitate bringing out the lessons and to help synthesize these into actionable outcomes.

This document was produced by the Stockholm Evaluation Unit.
14/03/2017

SSP was formed in the aftermath of a high profile depot crisis in South Africa in 2012/3, with six organisations, already dealing with drug stock outs joining forces to tackle the issue. The different organisations brought different skills to the table. Largely focused on anti-retrovirals (ARVs) and TB medication, from the beginning the SSP has tasked itself to hold government accountable, to perform a watchdog role and to present the patient view on stock outs.

This publication was produced at the request of MSF OCB, under the management of the Stockholm Evaluation Unit. It was prepared independently by Andrew McKenzie and Timothy McCann.
11/01/2017